Psychedelics And The National Institutes Of Health—How Do They Relate?

As David Hodes first noted in The Green Market Report, the U.S. National Institutes of Health (NIH)’s growing interest in psychedelic studies is remarkable. 

The agency annually invests about $41.7 billion in research as a whole, while more than 80 percent of the funding is awarded for extramural research through 50,000 competitive grants to researchers at universities, schools and other research institutions. 

In a recent reply letter to Sen. Brian Schatz, the NIH stated that it is currently funding 57 psychedelics projects for a total $34.4 million, including 36 applied studies for the National Institute of Mental Health (NIMH). The agency has also been working with the , the DEA, and the White House Office of National Drug Control Policy to facilitate the task of obtaining a registration to conduct research with controlled substances like psychedelics.

Yet despite fund-granting, the NIH believes that issues in psychedelics research still exist in what NIH directives have called a “knowledge gap,” partly due to insufficient diversity amongst participants of trials. 

They were referring to racial and ethnical diversity and to participants with diverse medical histories, too. The fact is that most psychedelics trials …

Full story available on Benzinga.com

More Psychedelics And The National Institutes Of Health—How Do They Relate?